People who suffer from insomnia have problems getting to sleep or remaining asleep. The disorder may be mild or chronic. It may also come and go. The good news is that the majority of cases of insomnia may be resolved by people themselves, without the assistance of sleep doctors or the use of prescription or over-the-counter sleeping aids. Insomnia can be treated (and/or reversed), but it will require some time and work. The gold standard for the treatment of chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I). CBT-I aids in overcoming underlying reasons for sleep issues, unlike sleeping drugs.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/958
Market information
According to estimates, the global market for insomnia therapy will be worth US$3,240.1 million by the end of the year.
Drivers
Over the projected period, the global market for insomnia treatment is anticipated to increase as a result of rising demand for safe & efficient insomnia treatment caused by the presence of a sizable population pool worldwide. For instance, Pear Therapeutics announced the release of Somryst, a prescription digital therapy for people over the age of 22, in November 2020. Somerset trains the brain and body to go asleep using CBT-I. In order to educate the patient how to enhance their sleep, the treatment leads them through lessons and difficulties throughout their programme, including algorithm-driven sleep restriction.
Opportunities
During the projection period, companies in the worldwide market for insomnia treatment should benefit from significant growth potential due to a rise in public awareness, the development of new technologies, and the introduction of innovation. For instance, the government was urged to include sleep in its Change for life global health action plan and to promote sleep as being as crucial to good health as diet and exercise when the Sleep Council and The Sleep Charity (UK) released what they dubbed the “Wake Up Call” sleep declaration in March 2020.
Restraints
Major challenges that are anticipated to limit the growth of the worldwide insomnia treatment market include misconceptions about the importance of insomnia, non-pharmacological treatments, and patient non-adherence due to the typical adverse effects of insomnia medicines. For instance, both non-pharmacologic and pharmaceutical therapy can be used to treat insomnia. Non-pharmacologic treatments include multicomponent therapy, relaxation therapy, cognitive behaviour therapy, sleep hygiene, and paradoxical intention. Refractory instances might be referred to a sleep expert.
Impact
The word “coronasomnia,” sometimes known as “covidsomnia,” refers to sleep issues caused by stress from the COVID-19 epidemic. Insomnia brought on by COVID-19 is frequently linked to worry, anxiety, sadness, and other mental health issues caused by the epidemic. Such a significant event in life is likely to interfere with sleep and make existing sleep issues worse. A third of individuals (33%) saw a change in the quality of their sleep, 29% noted a change in the quantity of sleep they get each night, and 30% noticed a change in their ability to fall asleep, according to the American Academy of Sleep Medicine’s (AASM) Sleep Prioritization Survey 2020. The market for treatments for insomnia worldwide is thus anticipated to develop as a result of this.
Key Takeaways
The global market for insomnia treatments was estimated to be worth US$ 3,048.04 million in 2021 and is predicted to increase at a 6.6% CAGR from 2022 to 2028 reaching US$ 4,752.2 million.
The medicine segment dominated the worldwide insomnia treatment market in 2021, accounting for 95.5% of the market’s value share. Increasing approval and the introduction of new products are anticipated to fuel the sector’s expansion over the course of the forecast period.
Market Trends
During the projected period, it is anticipated that the worldwide market for insomnia therapy would rise due to the rising incidence of insomnia. The most prevalent sleep condition, for instance, is insomnia. About 50 to 70 million Americans have insomnia each year, according to the American Sleep Association. Because of how common it is, 33% to 50% of adults report having insomnia symptoms.
During the projected period, the market for worldwide insomnia treatment is anticipated to develop due to the existence of supportive organisations focused on treating insomnia. For instance, the Canadian Sleep Society is dedicated to enhancing sleep for Canadians by supporting research, promoting high-quality clinical treatment, educating professionals and individuals, and advocating for night and sleep disorders medicine.
Competitive Landscape
Electromedical Products International Inc., Sanofi, Ebb Therapeutics, Pfizer Inc., Pharmaceutical Company, Takeda, Innovative Neurological Devices, Merck & Co. Inc., Cerêve Inc., and Paratek Pharmaceuticals Inc. are a few of the major companies competing in the global market for the treatment of insomnia.
Recent Developments
The U.S. Food and Drug Administration (FDA) approved Dayvigo as a new sleep medication in December 2020. (lemborexant). The medication will be offered in dosages of 5 mg or 10 mg, according to a press statement from Eisai, the medication’s maker.
Following permission from the US Food and Drug Administration, Dr. Reddy’s Laboratories introduced generic Ramelteon tablets used to treat insomnia in the U.S. market in July 2019. (USFDA).
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/958
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Insomnia therapeutics Market Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Insomnia therapeutics Market Industry Impact
Chapter 2 Global Insomnia therapeutics Market Competition by Types, Applications, and Top Regions and Countries
2.1 Global Insomnia therapeutics Market (Volume and Value) by Type
2.3 Global Insomnia therapeutics Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Insomnia therapeutics Market Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Insomnia therapeutics Market Analysis
Chapter 6 East Asia Insomnia therapeutics Market Analysis
Chapter 7 Europe Insomnia therapeutics Market Analysis
Chapter 8 South Asia Insomnia therapeutics Market Analysis
Chapter 9 Southeast Asia Insomnia therapeutics Market Analysis
Chapter 10 Middle East Insomnia therapeutics Market Analysis
Chapter 11 Africa Insomnia therapeutics Market Analysis
Chapter 12 Oceania Insomnia therapeutics Market Analysis
Chapter 13 South America Insomnia therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Insomnia therapeutics Market Business
Chapter 15 Global Insomnia therapeutics Market Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/958
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837